Frankfurt am Main (ots) - Pentahotels, die Lifestyle Hotelgruppe, besetzt ihre Geschäftsführung neu und ...
Solianis Monitoring finalizes clinical trial for non-invasive conti¬nuous glucose monitoring in patients with diabetes
Zurich (ots) - Solianis Monitoring Ltd reaches another milestone testing their Multisensor Glucose Monitoring System for non-invasive continuous glucose monitoring in daily life
The latest generation of Solianis' Multisensor Glucose Monitoring System with the final sensor configuration was tested in patients with diabetes in daily life. 20 patients wore the device between November 2009 and August 2010 for over 1'000 days during their normal day to day activities. Interim data evaluation shows that the device performs reliable and delivers continuous glucose information.
'I am convinced that the glucose information provided by this device can improve management of patients with diabetes significantly and I look forward to explore the integration of this system in my clinical routine', says Prof. Marc Donath, University Hospital Basel, Chief of Department Endocrinology, Diabetology and Metabolism and member of Solianis' Scientific Advisory Board.
'These encouraging results are another important step on our route towards non-invasive continuous glucose monitoring,' states Mario Stark, CEO of Solianis Monitoring Ltd. 'We now have the necessary data and proof to finalize the first generation system. This is the right time for us to engage with a strategic partner to bring the Multisensor Glucose Monitoring System to patients with diabetes and their caregivers for the benefit of the diabetes community, our shareholders and employees.'
Solianis Monitoring Ltd. is a Swiss medical device company developing an in¬novative non-invasive Continuous Glucose Monitoring (CGM) system for patients with diabetes, their relatives and health care professionals. Its unique and proprietary technology is integrated in a Multisensor Glucose Monitoring System (MGMS) which continuously delivers information on glucose variations. The current device is being tested to finalize the design and optimize the glucose information.
Solianis was incorporated in May 2005 and has so far been funded by private investors, the Pioneer Fond of the Zurich Cantonal Bank and the EGS Beteiligungen AG.
ots Originaltext: Solianis Monitoring AG